Attovia Therapeutics
ATTO
16.04
-0.38
-2.31%
Attovia Therapeutics
US · ATTO
#3464 by market cap
Listed 2026
16.04
-0.38
-2.31%
Live - 5344 symbols - heartbeat 427s ago
· 2026-10-08 10:00
Pre-market
16.97
+3.35%
After-hours
16.42
0.00%
- Market cap
- 732.25M
- P/E (TTM)i
- -10.40
- P/Bi
- -5.03
- EPSi
- -1.42
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on ATTO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
- Total institutional ownership rose 48.6 percentage points.
Institutional ownership
- Held by institutions
- 48.59% +48.59pp
- Institutions
- 10 +10
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund31.45%
Public Company10.47%
Mutual Fund4.51%
Hedge Fund2.15%
Individual/Insider1.58%
Other49.83%
Top holders as of 2026-08-07
Frazier Life Sciences Management, LP
15.27% · 6.97M sh
venBio LLC
9.16% · 4.18M sh
Alamar Biosciences, Inc.
7.07% · 3.23M sh
Deep Track Capital, LP
7.03% · 3.21M sh
Goldman Sachs Asset Management, L.P.
4.31% · 1.97M sh
Sanofi
2.37% · 1.08M sh
Redmile Group, LLC
2.15% · 982.85K sh
Tao Fu
1.20% · 548.56K sh
The Goldman Sachs Group, Inc.
1.03% · 468.57K sh
Petter Veiby
0.23% · 104.95K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
27 filings tracked · 15 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 15.27% |
| Tao Fu | Chief Executive Officer | 1.20% |
| Petter Veiby | Chief Scientific Officer | 0.23% |
| Angie You | Independent Director | 0.12% |
| Zaneta Odrowaz | Chief Business Officer, Treasurer & Secretary | 0.02% |
| Hubert Chen | Chief Medical Officer | 0.01% |
| Sanofi | -- | -- |
| Mitchell Gold | Independent Director | -- |
| Goldman Sachs Asset Management, L.P. | -- | -- |
| Redmile Group, LLC | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-05 | Sanofi | -- | Private Acquisition | +300,000 | $17.00 |
| 2026-08-05 | Sanofi | -- | Derivative Exercise and Retained | +782,855 | -- |
| 2026-08-05 | Redmile Group, LLC | -- | Private Acquisition | +200,000 | $17.00 |
| 2026-08-05 | Redmile Group, LLC | -- | Derivative Exercise and Retained | +782,854 | -- |
| 2026-08-05 | venBio LLC | -- | Private Acquisition | +382,352 | $17.00 |
| 2026-08-05 | venBio LLC | -- | Derivative Exercise and Retained | +3,799,015 | -- |
| 2026-08-05 | Deep Track Capital, LP | -- | Derivative Exercise and Retained | +1,957,138 | -- |
| 2026-08-05 | Frazier Life Sciences Management, LP | -- | Private Acquisition | +588,235 | $17.00 |
| 2026-08-05 | Frazier Life Sciences Management, LP | -- | Derivative Exercise and Retained | +5,490,629 | -- |
| 2026-08-04 | Goldman Sachs Asset Management, L.P. | -- | Open Market Derivative Acquisiti | +105,807 | -- |
| 2026-08-03 | Sanofi | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Mitchell Gold | Independent Director | Other Derivative Acquisition | +27,000 | $17.00 |
| 2026-08-03 | Mitchell Gold | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Angie You | Independent Director | Other Derivative Acquisition | +27,000 | $17.00 |
| 2026-08-03 | John Smither | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Hubert Chen | Chief Medical Officer | Other Derivative Acquisition | +140,000 | $17.00 |
| 2026-08-03 | Broad Street Principal Investments, L.L.C. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Tao Fu | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Alamar Biosciences, Inc. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Zaneta Odrowaz | Chief Business Officer, Treasurer & Secretary | Other Derivative Acquisition | +140,000 | $17.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:00:18 · For reference only, not investment advice and not tailored to your situation.